Andersen Anders S, Sandvang Dorthe, Schnorr Kirk M, Kruse Thomas, Neve Søren, Joergensen Bo, Karlsmark Tonny, Krogfelt Karen A
Department of Microbiological Surveillance and Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
J Antimicrob Chemother. 2010 Aug;65(8):1646-54. doi: 10.1093/jac/dkq165. Epub 2010 Jun 11.
OBJECTIVES: Commercially produced sterile green bottle fly Lucilia sericata maggots are successfully employed by practitioners worldwide to clean a multitude of chronic necrotic wounds and reduce wound bacterial burdens during maggot debridement therapy (MDT). Secretions from the maggots exhibit antimicrobial activity along with other activities beneficial for wound healing. With the rise of multidrug-resistant bacteria, new approaches to identifying the active compounds responsible for the antimicrobial activity within this treatment are imperative. Therefore, the aim of this study was to use a novel approach to investigate the output of secreted proteins from the maggots under conditions mimicking clinical treatments. METHODS: cDNA libraries constructed from microdissected salivary glands and whole maggots, respectively, were treated with transposon-assisted signal trapping (TAST), a technique selecting for the identification of secreted proteins. Several putative secreted components of insect immunity were identified, including a defensin named lucifensin, which was produced recombinantly as a Trx-fusion protein in Escherichia coli, purified using immobilized metal affinity chromatography and reverse-phase HPLC, and tested in vitro against Gram-positive and Gram-negative bacterial strains. RESULTS: Lucifensin was active against Staphylococcus carnosus, Streptococcus pyogenes and Streptococcus pneumoniae (MIC 2 mg/L), as well as Staphylococcus aureus (MIC 16 mg/L). The peptide did not show antimicrobial activity towards Gram-negative bacteria. The MIC of lucifensin for the methicillin-resistant S. aureus and glycopeptide-intermediate S. aureus isolates tested ranged from 8 to >128 mg/L. CONCLUSIONS: The TAST results did not reveal any highly secreted compounds with putative antimicrobial activity, implying an alternative antimicrobial activity of MDT. Lucifensin showed antimicrobial activities comparable to other defensins and could have potential as a future drug candidate scaffold, for redesign for other applications besides the topical treatment of infected wounds.
目的:全球各地的从业者成功地使用商业生产的无菌绿蝇丽蝇蛆来清洁多种慢性坏死伤口,并在蛆清创疗法(MDT)期间降低伤口细菌负荷。蛆的分泌物具有抗菌活性以及其他对伤口愈合有益的活性。随着多重耐药菌的出现,识别该治疗中负责抗菌活性的活性化合物的新方法势在必行。因此,本研究的目的是使用一种新方法来研究在模拟临床治疗的条件下蛆分泌蛋白的输出情况。 方法:分别从显微解剖的唾液腺和整个蛆构建的cDNA文库,用转座子辅助信号捕获(TAST)处理,这是一种用于鉴定分泌蛋白的技术。鉴定了几种昆虫免疫的假定分泌成分,包括一种名为lucifensin的防御素,它在大肠杆菌中作为Trx融合蛋白重组产生,使用固定化金属亲和色谱和反相HPLC纯化,并在体外针对革兰氏阳性和革兰氏阴性细菌菌株进行测试。 结果:Lucifensin对肉葡萄球菌、化脓性链球菌和肺炎链球菌(MIC 2 mg/L)以及金黄色葡萄球菌(MIC 16 mg/L)有活性。该肽对革兰氏阴性细菌没有显示出抗菌活性。所测试的耐甲氧西林金黄色葡萄球菌和糖肽中介金黄色葡萄球菌分离株的lucifensin MIC范围为8至>128 mg/L。 结论:TAST结果未揭示任何具有假定抗菌活性的高分泌化合物,这意味着MDT具有另一种抗菌活性。Lucifensin显示出与其他防御素相当的抗菌活性,并且有可能作为未来的药物候选支架,用于除感染伤口局部治疗之外的其他应用重新设计。
J Antimicrob Chemother. 2010-8
Mikrobiyol Bul. 2021-1
Cell Mol Life Sci. 2009-11-18
Antimicrob Agents Chemother. 2015-5
Cell Tissue Res. 2013-4-28
Mater Today Bio. 2024-10-22
Forensic Sci Med Pathol. 2024-12
Front Vet Sci. 2023-8-17
Clin Orthop Relat Res. 2011-4
Cell Mol Life Sci. 2009-11-18
Microbiology (Reading). 2009-11-5
Int J Antimicrob Agents. 2009-8
Sci China C Life Sci. 2009-1
Insect Mol Biol. 2009-2